Breast cancer: importance of tumor markers
DOI:
https://doi.org/10.33448/rsd-v12i6.41945Keywords:
Tumor; Breast cancer; Tumor markers.Abstract
Breast cancer is the most common pathology among women in Brazil and in the world, responsible for high mortality rates, and considered a major public health problem. Breast cancer has several tumor markers that can be found at different stages of tumor development from the beginning to possible recurrences. Tumor biomarkers are used for the differential diagnosis in symptomatic patients, clinical staging, establishment of the diagnosis, monitoring of therapeutic efficiency, location of metastases, treatment by immunoradiotherapy and early detection of recurrence. Therefore, a narrative bibliographic review was carried out in order to demonstrate the importance of biomarkers, consulting publications available in the main databases such as Google Scholar, PubMed, SciELO, as well as articles published by INCA. 22 articles were selected that contributed to the conclusion of the study, which show the great importance of tumor biomarkers in the evaluation of the tumor since it is discovered until its reappearance, being able to evaluate the prognosis, degree of staging, treatment and later to monitor its effectiveness.
References
Almeida J. R. C. (2004). Farmacêuticos em oncologia: uma nova realidade. Atheneu; 61-72.
Almeida J. R. C et al. (2007). Marcadores Tumorais: Revisão de Literatura. Revista Brasileira de Cancerologia, 53(3): 305-316.
Andrade, S. A. F. (2014). Câncer de mama: um problema de saúde pública. Revista UNILUS Ensino e Pesquisa, 11(23):70.
Barbosa, M. G.A. et al. (2020). Alterações citológicas e marcadores tumorais específicos para o câncer de mama. Braz. J. of Develop, 6(8): 59977-59992.
Bernardes, N. B., Sá, A. C. F., Facioli, L. S., Ferreira, M. L., Sá, O. R. & Costa, R. M. (2019). Câncer de Mama X Diagnóstico. Id on Line Revista Multidisciplinar e de Psicologia, Jaboatão dos Guararapes, 13(44): 877-885.
Cabral, R.F. et al. (2020). Use of tumor markers for câncer diagnosis: a literature review. Research, Society and Development, .9(11): e8391110601.
Cambruzzi E., Lima R. de & Teixeira S. L, et al. (2014). The relationship between serum levels of CA 125 and the degree of differentiation in ovarian neoplasms. J Bras Patol e Med Lab, 50: 20-25.
Cândido, C. et al. (2016). A carcinogênese e o câncer de mama. Revista Maiêutica Indaial, 4(1): 45-52.
Chan D. W, Beveridge R.A, Muss H, Fritsche H.A, Hortobagyi G., & Theriault R, et al. (1997). Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol,15(6):2322-2328.
Cintra, J. R et al. (2012). Perfil imuno-histoquímico e variáveis clinicopatológicas no câncer de mama. Rev. Assoc. Med. Bras, 58(2):178-187.
Cote R. J & Taylor C. R. (1994). Immunohistochemical detection of steroid hormone receptors. In: Taylor C. R, Cote RJ, eds. Immunomicroscopy: a diagnostic tool for the surgical pathologist. 2th ed. Philadelphia: W.B. Saunders. (Major problems in pathology, vol. 19).
Conley S. J, Bosco E. E & Tice D. A, et al. (2016). HER2 drives Mucin-like 1 to control proliferation in breast cancer cells. Oncogene, 35: 4.225-4234.
Donepudi M. S, Kondapalli K. & Amos S. J, et al. (2014). Breast cancer statistics and markers. J Cancer Res Ther, 10: 506-511.
Francisco, P. S. B. et al. (2020). Prevalência de diagnóstico e tipos de câncer em idosos: dados da Pesquisa Nacional de Saúde 2013. Rev. Bras. Geriatr. Gerontol, 23(2): e200023.
Guimarães R. C, Rodrigues V.H, Pádua C. A. J., & Andrade F. A. F. (2002). Uso dos marcadores tumorais na prática clínica. Prática Hospitalar (Belo Horizonte), IV (23):1-8.
Guedes Neto E. P, Monteggia P., Fuhrmeister F., Basso A., & Siqueira D. P. (1995). Avanços médicos: marcadores tumorais versus câncer de mama. Rev Bras Cancerol, 41(1):39-42.
Gusterson B. A, Gelber R. D, Goldhirsch A., Price K. N, SäveSöderborgh J., & Anbazhagan R, et al. (1992). Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol,10(7):1049-1056.
Molland J. G, Barraclough B. H, Gebski V., Milliken J., & Bilous M. (1996). Prognostic significance of c-erbb-2 oncogene in axillary nodenegative breast cancer. Aust N Z J Surg, 66:64-70.
Pereira da silva, M. Aparecida de Campos, R., & Ucelli Simionii, P. (2020). Biomarcadores sorológicos tumorais de câncer de mama: revisão da literatura. SAÚDE REV., Piracicaba, 20(52): 67-73.
Rosen P. P. (1997). Breast Pathology. Philadelphia: Lippincott-Raven.
Van Poznak C., Somerfield M. R., & Bast R. C, et al. (2015). Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 33: 2.695-2.704.4
Veronesi U., Luini A., Costa A., & Andreoli C. (2002). Mastologia oncológica. Milão: Medsi.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Stela Morais Jacinto ; Helineide Cristina Campos Brum
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
